Transgenomic Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2016
2017
2018
Cash & Short Term Investments
71,753.00
60,021.00
145,128
Other Current Assets
685.00
3,014.00
3,674
Total Current Assets
72,438.00
63,035.00
149,602
Net Property, Plant & Equipment
4,859.00
6,778.00
10,245
Intangible Assets
21,359.00
21,359.00
21,359
Other Assets
106,907.00
107,375.00
106,445
Total Assets
205,563.00
198,547.00
287,651
Accounts Payable
462.00
4,594.00
Other Current Liabilities
11,546.00
7,491.00
Total Current Liabilities
12,008.00
12,085.00
Deferred Taxes
18,520.00
6,039.00
Other Liabilities
63,348.00
81,042.00
Total Liabilities
93,876.00
99,166.00
Common Equity (Total)
38,590.00
93,515.00
Total Shareholders' Equity
111,687.00
99,381.00
Total Equity
111,687.00
99,381.00
Liabilities & Shareholders' Equity
205,563.00
198,547.00
Preferred Stock (Carrying Value)
150,277.00
192,896.00

About Transgenomic

View Profile
Address
29 Hartwell Avenue
Lexington Massachusetts 02421
United States
Employees -
Website http://www.translate.bio
Updated 07/08/2019
Translate Bio, Inc. engages in the research and development of therapeutic drugs. Its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases. The company was founded in 2011 and is headquartered in Cambridge, MA.